{"url_path":"/sec/abos/8-k/2026-06-03/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-03","source_url":"https://www.sec.gov/Archives/edgar/data/1576885/0001628280-26-040447-index.html","accession_number":"0001628280-26-040447","cik":"0001576885","ticker":"ABOS","issuer_name":"Acumen Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1576885/0001628280-26-040447-index.html","primary_entity_key":"0001576885","primary_entity_name":"Acumen Pharmaceuticals, Inc."},"word_count":290,"has_tables":true,"body_markdown":"Item 5.07    Submission of Matters to a Vote of Security Holders.\n\nOn June 3, 2026, Acumen Pharmaceuticals, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). The stockholders considered three proposals at the Annual Meeting, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 23, 2026. Of the 72,227,580 shares outstanding as of the record date, 57,051,456 shares, or approximately 78.99%, were present or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting.\n\nProposal No. 1: The stockholders elected three nominees to serve as Class II directors until the 2029 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows:\n\nNameVotes ForVotes WithheldBroker Non-Votes\n\nGeorge Golumbeski, Ph.D.37,305,71168,82019,676,925\n\nDerrell Porter, M.D.30,926,4946,448,03719,676,925\n\nLaura Stoppel, Ph.D.30,812,5596,561,97219,676,925\n\nProposal No. 2: The stockholders ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes were cast as follows:\n\nVotes For\n\nVotes Against\n\nAbstained\n\nRatification of appointment of Ernst & Young LLP\n56,934,900113,0743,482\n\nProposal No. 3: The stockholders approved the Company’s Amended and Restated 2021 Equity Incentive Plan. The votes were cast as follows:\n\nVotes For\n\nVotes Against\n\nAbstained\nBroker Non-Votes\n\nApproval of the Company’s Amended and Restated 2021 Equity Incentive Plan30,731,7766,618,62124,13419,676,925\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nAcumen Pharmaceuticals, Inc.\n\nDated: June 3, 2026By:/s/ Derek Meisner\n\nDerek Meisner\n\nChief Legal Officer"}